



President's Cancer Panel

2004–2005 Meeting Series

Translating Research to Reduce the Burden of Cancer

Upcoming Meetings

On each date shown below, the Panel will hold a meeting with invited speakers. Meetings of the President's Cancer Panel are open to the general public. All are welcome to attend.

August 30, 2004

**Hosted by the UCSF Comprehensive Cancer Center
Grand Hyatt Hotel
San Francisco, CA**

September 27, 2004

**Hosted by The Ohio State Comprehensive Cancer Center-Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute
Columbus, OH**

November 1, 2004

**Hosted by the University of Texas M.D. Anderson
Cancer Center
Houston, TX**

January 24, 2005

**Hosted by the
Memorial Sloan-Kettering Cancer Center
New York, NY**

Who Will Participate

- ◆ Cancer Center Representatives
- ◆ Basic and Clinical Scientists
- ◆ Practitioners/Principal Investigators/Community Oncologists
- ◆ Public Affairs/Communications Specialists
- ◆ Academic Institution Representatives
- ◆ Intellectual Property Counsel/Ethics Officials
- ◆ Government Officials and Regulatory Experts
- ◆ Institutional Review Board Representatives
- ◆ Private Sector Biotechnology/Pharmaceutical Companies
- ◆ Health Systems Specialists
- ◆ Advocates
- ◆ Consumers

Background

- ◆ The National Institutes of Health Roadmap Initiatives include, among others, projects focusing on technology development, structural barriers to interdisciplinary research, public/private partnerships, clinical research workforce training, clinical research information, translational research core services, and regional translational research centers.
- ◆ The National Cancer Institute recently released a document, *Advancing Translational Cancer Research: A Vision of the Cancer Center and SPORE Programs of the Future*.
- ◆ The National Cancer Policy Board of the Institute of Medicine will soon release the report, *Shortening the Time Line for New Cancer Treatments*.
- ◆ *Large-Scale Biomedical Science: Exploring Strategies for Future Research* was recently released by the Institute of Medicine.
- ◆ A joint Task Force was recently formed between the National Cancer Institute and the Food and Drug Administration to work together on issues of development and review processes for new cancer drugs and technologies.

Questions to be Explored

- ◆ What are the barriers to translating research into reductions in the burden of cancer?
- ◆ What is the role of academic medical centers in translating research into clinical practice?
- ◆ What are the best mechanisms for moving research into communities?

Possible Outcomes

- ◆ Strategies to increase accrual to clinical trials
- ◆ Potential collaboration for improved efficacy of clinical trials
- ◆ Identification of barriers to peer review of clinical research
- ◆ Identification of regulatory impediments to the application of clinical research
- ◆ Development of programs to provide rapid access of research outcomes to the general public

For more information about this series of meetings, please visit the Panel's Web site at pcp.cancer.gov, or contact Karen Parker at the President's Cancer Panel, 301-451-9462, klparker@mail.nih.gov.